Role of plasminogen activator inhibitor‑1 in the diagnosis and prognosis of patients with Parkinson's disease

  • Authors:
    • Hong Pan
    • Ying Zhao
    • Zhengping Zhai
    • Jinyu Zheng
    • Yong Zhou
    • Qijin Zhai
    • Xiangyang Cao
    • Jisha Tian
    • Liandong Zhao
  • View Affiliations

  • Published online on: April 17, 2018     https://doi.org/10.3892/etm.2018.6076
  • Pages: 5517-5522
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Parkinson's disease is a neurodegenerative disease that frequently results in memory disorders, cognitive decline and dementia. Previous studies have reported that plasminogen activator inhibitor‑1 (PAI‑1) serves an important role in cardiovascular disease risk, adiposity, insulin resistance and inflammation. However, the role of PAI‑1 in diagnosis and prognosis of patients with Parkinson's disease following deep brain stimulation (DBS) has not reported, to the best of our knowledge. Therefore, the purpose of the present study was to investigate the clinical significance of PAI‑1 in patients with Parkinson's disease. Plasma PAI‑1 levels were measured in 102 patients with Parkinson's disease who underwent DBS. It was demonstrated that plasma PAI‑1 levels were significantly increased in patients with Parkinson's disease compared with healthy individuals (P<0.01). Patients with Parkinson's disease received DBS presented significantly improved cognitive competence compared with controls (P<0.01). DBS significantly decreased plasma PAI‑1 levels in patients with Parkinson's disease compared with controls (P<0.05). It was also observed that plasma PAI‑1 levels were significantly negatively associated with cognitive function for patients with Parkinson's disease (P<0.01). In conclusion, these findings demonstrated that the degree of Parkinson's disease severity is positively associated with circulating levels of plasma PAI‑1 levels, which suggests that PAI‑1 may be a potential diagnostic and prognostic marker for patients with Parkinson's disease.
View Figures
View References

Related Articles

Journal Cover

June-2018
Volume 15 Issue 6

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Pan H, Zhao Y, Zhai Z, Zheng J, Zhou Y, Zhai Q, Cao X, Tian J and Zhao L: Role of plasminogen activator inhibitor‑1 in the diagnosis and prognosis of patients with Parkinson's disease. Exp Ther Med 15: 5517-5522, 2018
APA
Pan, H., Zhao, Y., Zhai, Z., Zheng, J., Zhou, Y., Zhai, Q. ... Zhao, L. (2018). Role of plasminogen activator inhibitor‑1 in the diagnosis and prognosis of patients with Parkinson's disease. Experimental and Therapeutic Medicine, 15, 5517-5522. https://doi.org/10.3892/etm.2018.6076
MLA
Pan, H., Zhao, Y., Zhai, Z., Zheng, J., Zhou, Y., Zhai, Q., Cao, X., Tian, J., Zhao, L."Role of plasminogen activator inhibitor‑1 in the diagnosis and prognosis of patients with Parkinson's disease". Experimental and Therapeutic Medicine 15.6 (2018): 5517-5522.
Chicago
Pan, H., Zhao, Y., Zhai, Z., Zheng, J., Zhou, Y., Zhai, Q., Cao, X., Tian, J., Zhao, L."Role of plasminogen activator inhibitor‑1 in the diagnosis and prognosis of patients with Parkinson's disease". Experimental and Therapeutic Medicine 15, no. 6 (2018): 5517-5522. https://doi.org/10.3892/etm.2018.6076